SDAI gets shareholder nod to enter biotech and anti-ageing business

It targets the longevity market with skincare, supplements and moxibustion push.

SDAI Limited has obtained shareholder approval to diversify into the biotechnology business at an extraordinary general meeting held on 30 April.

In a statement, the company said the diversification will cover biotechnology activities related to the development, distribution, and provision of anti-ageing and longevity-focused healthcare products and services.

SDAI cited growth in the global anti-ageing market, estimated at $101.51b (USD80b) in 2025 and projected to reach $173.96b (USD137.1b) by 2035.

It also referenced the Research, Innovation and Enterprise 2030 (RIE2030) plan, which will invest $37b in research and innovation from April 2026, including healthy longevity initiatives.

The group said it has already begun activities in the sector, including a strategic cooperation agreement with LiveBeyond Pte. Ltd. in August 2025 for anti-ageing research and applications.

In December 2025, SDAI launched its Bluecode Biotech B-III skincare series in China and Singapore, with products distributed through e-commerce platforms including Lazada and Shopee.

In January 2026, it entered into a joint venture with Hubei Qiai Group Co., Ltd., QCM Holdings Pte. Ltd., and QCM International Pte. Ltd. to expand moxibustion-related products in ASEAN including setting up a moxibustion experience centre in Singapore.

SDAI said the diversification will allow it to pursue biotechnology-related transactions more efficiently without requiring separate shareholder approvals for each deal.

$1.27 = USD1

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia